Table 3.
Cilengitide + Gemcitabine n = 46 | Gemcitabine n = 43 | |||
No. patients | % | No. patients | % | |
Complete response | 0 | 0% | 1 | 2% |
Partial response | 8 | 17% | 5 | 12% |
Stable disease | 17 | 37% | 18 | 42% |
Progressive disease | 12 | 26% | 10 | 23% |
Missing/not assessable | 9 | 20% | 9 | 21% |
Response rate | 8 | 17% | 6 | 14% |
Tumor growth control | 25 | 54% | 24 | 56% |